226950 — OliX Pharmaceuticals Balance Sheet
0.000.00%
- KR₩3tn
- KR₩3tn
- KR₩6bn
Annual balance sheet for OliX Pharmaceuticals, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 68,111 | 49,757 | 61,872 | 25,925 | 12,414 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 518 | 552 | 1,147 | 5,283 | 1,082 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 69,047 | 52,240 | 65,046 | 32,142 | 15,534 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6,180 | 31,525 | 37,232 | 43,910 | 51,385 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 78,577 | 86,672 | 132,651 | 102,825 | 71,249 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,488 | 40,365 | 39,543 | 6,563 | 30,060 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 33,292 | 68,151 | 66,744 | 52,971 | 53,400 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 45,286 | 18,521 | 65,907 | 49,855 | 17,849 |
| Total Liabilities & Shareholders' Equity | 78,577 | 86,672 | 132,651 | 102,825 | 71,249 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |